Harnessing the power of the endocannabinoid system.

Our goal is to become a global leader in the development of safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions. OCT's primary focus is on the development for indications in severe, chronic pain conditions, that remain one of the biggest challenges facing society today.

 

Find out more

Our Approach

OCT has a range of compounds in drug development, including proprietary cannabinoid derivatives, natural phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, long-term market value, and market exclusivity across all activities.

 

Find out more

Meet the Team

With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCT's team is committed to excellence. Together, we are passionate about delivering breakthrough therapies for life-threatening conditions with a significant unmet medical need.

 

Find out more

Recent news, reports & resources

 

All News

  •

    Oxford Cannabinoid Technologies "officially on the way" after first dosing

    27 July 2023 proactive interview
    Find out more

  • Oxford Cannabinoid Technologies Takes Pain Drug into Phase I; Appoints Leading Pain Expert

    27 July 2023 Proactive
    Find out more

  • OXFORD CANNABINOID TECHNOLOGIES ACHIEVES MILESTONE IN PHASE ONE CLINICAL TRIAL #OCTP

    27 July 2023 stockbox
    Find out more

View more news & media

Get in touch

Oxford Cannabinoid Technologies Ltd

Prama House
267 Banbury Road
Oxford
OX2 7HT

Find us on a map